The Lupus Research Alliance is pleased and very encouraged to share a promising scientific breakthrough reported in the New York Times with real potential to revolutionize lupus treatment. Just reported in the prestigious journal Nature, scientists in Dr. Alexander Marson's lab at the University of California, San Francisco have developed an innovative way to engineer genes of the body's immune system to treat immunologic diseases like lupus, rheumatoid arthritis, cancer and HIV.
Levels of certain antibodies are significantly associated with particular clinical characteristics of systemic lupus erythematosus (SLE), and could be used to assess disease activity in patients, a study finds.
The study, “Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity,” was published in the journal Reumatismo.
Neovacs, a French biotech, obtained positive Phase IIb results showing its lupus vaccine could be effective in treating this severe autoimmune disease.
Its lupus vaccine works by stimulating the patient’s immune system to produce antibodies against a protein called IFNα that regulates the immune system and is involved in the disease.
Two studies by researchers at UT Southwestern Medical Center could lead to new treatments for lupus and other autoimmune diseases and strengthen therapies for viral, bacterial, and parasitic infections.
More than 30 years ago while studying to be a veterinarian, Chris Goodnow became fascinated with autoimmune diseases. The interest was cemented when his mother was diagnosed with lupus...
We enrolled 213 childhood-onset SLE patients, and ethnicity data were available for 206 patients: white (31%), Asian (30%), South Asian (15%), black (10%), Latino/Hispanic (4%), Aboriginal (4%), and Arab/Middle Eastern (3%)...
In this large SLE sample, there was a suggestion of higher lymphoma risk with exposure to cyclophosphamide and high cumulative steroids...
A clinical trial with 149 patients suffering from systemic lupus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.